US-based drug maker Eli Lilly (NYSE:LLY) said on Thursday that is suing six more entities that are accused of selling counterfeit Mounjaro, Reuters reported on Thursday.
Medical spas and wellness centres are among the businesses facing legal action for allegedly selling products claimed to contain tirzepatide, the active ingredient in Lilly's diabetes drug Mounjaro.
Eli Lilly is the only company that has been approved by US Food and Drug Administration to sell the drug.
Lilly has also warned consumers against the use of counterfeit, fake, compounded, and any other unsafe or untested versions of what is claimed to be tirzepatide.
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
bioMérieux secures US FDA clearance for new gastrointestinal diagnostic panel
EssilorLuxottica expands med-tech portfolio with Cellview acquisition
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Hemab Therapeutics reveals interim data from ongoing HMB-001 phase two study
AbbVie's EMBLAVEO receives US FDA approval for complicated intra-abdominal infections
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Lilly's Omvoh shows sustained efficacy in Crohn's disease after two years
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
BioArctic reports strong royalty growth from Leqembi sales in Q4 2024